Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and pr...
Q2 2026
Aug 13, 2026
Q1 2026
Mar 31, 2026
FY 2025
Q4 2025
Q3 2025
Nov 13, 2025